History and therapeutic use of MAO-A inhibitors: A historical perspective of MAO-A inhibitors as antidepressant drug

Current Topics in Medicinal Chemistry

Volumn 12, Issue 20, 2012, Pages 2275-2282

  Yáñez, Matilde ^a,b   Padín, Juan Fernando ^b   Arranz Tagarro, Juan Alberto ^a,b   Camiña, Mercedes ^a   Laguna, Reyes ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Antidepressants; Depression; Iproniazid; MAO A selective inhibitors; MAOIs; Moclobemide

Indexed keywords

AMIFLAMINE; AMPHETAMINE; BAZINAPRINE; BEFLOXATONE; BENMOXIN; BROFAROMINE; CIMOXATONE; EPROBEMIDE; FURAZOLIDONE; IMIPRAMINE; IPROCLOZIDE; IPRONIAZID; ISOCARBOXAZID; ISONIAZID; LINEZOLID; METHYLENE BLUE; METRALINDOLE; MINAPRINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; PARGYLINE; PHENELZINE; PIRLINDOLE; PROCARBAZINE; RESERPINE; SAFRAZINE; SERCLOREMINE; TOLOXATONE; TRANYLCYPROMINE; UNINDEXED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BLURRED VISION; CHILL; CLINICAL TRIAL (TOPIC); CONFUSION; CONVULSION; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HEADACHE; HUMAN; HYPERTENSIVE CRISIS; LIBIDO DISORDER; LIVER TOXICITY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; SIDE EFFECT; SLEEP DISORDER; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84874858227     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805220011     Document Type: Article

References (99)

1. Delay, J.; Laine, B.; Buisson, J.F. The action of isonicotinyl-hydrazide used in the treatment of depressive states. Ann. Med. Psychol., 1952, 110, 689-692.
2. Zeller, E.A.; Barsky, J. In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med., 1952, 81, 459-461.
3. Selikoff, I.J.; Robitzek, E.H.; Ornstein, G.G. Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. J. Am. Med. Assoc., 1952, 150, 973-980.
4. Lopez-Munoz, F.; Alamo, C.; Juckel, G.; Assion, H.J. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J. Clin. Psychopharmacol, 2007, 27, 555-559.
5. Chessin, M.; Kramer, E.R.; Scott, C.C. Modifications of the pharmacology of reserpine and serotonin by iproniazid. J. Pharm. Exp. Ther., 1957, 119, 453-460.
6. th June, 2012].
7. Loomer, H.P.; Saunders, J.C.; Kline, N.S. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr. Res. Rep. Am. Psychiatr. Assoc., 1957, 8, 129-141.
8. Crane, G.E. Iproniazid (marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiatr. Res. Rep. Am. Psychiatr. Assoc., 1957, 8, 142-152.
9. Raviña Ruvira, E. Medicamentos, un viaje a lo largo de la evolución histórica del descubrimiento de fármacos Universidad de Santiago de Compostela, 2008.
10. Healy, D. The Antidepressant Era; Oxford University Press: Cambridge, Massachusetts; London, UK, 1997.
11. Burger, A.; Yost, W.L. Arylcycloalkylamines. I. 2-Phenylcyclo propylamine. J. Am. Chem. Soc., 1948, 70, 2198-2201.
12. Maass, A.R.; Nimmo, M.J. A new inhibitor of serotonin metabolism. Nature, 1959, 184(SUPPL. 8), 547-548.
13. Tedeschi, R.E.; Tedeschi, D.H.; Ames, P.L.; Cook, L.; Mattis, P.A.; Fellows, E.J. Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase. Proc. Soc. Exp. Biol. Med., 1959, 102, 380-381.
14. Atkinson, R.M.; Ditman, K.S. Tranylcypromine: a review. Clin. Pharmacol. Ther., 1965, 6, 631-655.
15. Ban, T.A. Pharmacotherapy of depression: a historical analysis. J. Neural. Transm, 2001, 108, 707-716.
16. Ayd, F.J. Invited ACNP Lecture. The early history of modern psychopharmacology. Neuropsychopharmacology, 1991, 5, 71-84.
17. Saura Marti, J.; Kettler, R.; Da Prada, M.; Richards, J. G. Molecular neuroanatomy of MAO-A and MAO-B. J Neural. Transm. Suppl., 1990, 32, 49-53.
18. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci, 1999, 22, 197-217.
19. Fulton, B.; Benfield, P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs, 1996, 52, 450-474.
20. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. Biol., 2004, 338, 103-114.
21. Molina, E.; Sobarzo-Sanchez, E.; Speck-Planche, A.; Matos, M. J.; Uriarte, E.; Santana, L.; Yañez, M.; Orallo, F. Monoamino Oxidase A: an interesting pharmacological target for the development of multi-target QSAR. Mini Rev. Med. Chem., 2012, 12(10), 947-958.
22. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43, 4747-4758.
23. Vallejos, G.; Rezende, M.C.; Cassels, B.K. Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines--a QSAR study. J. Comput. Aided. Mol. Des., 2002, 16, 95-103.
24. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Befani, O.; Meninno, T.; Agostinelli, E.; Palmegiani, P.; Turini, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; La Torre, F. Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors. J. Med. Chem., 2005, 48, 4220-4223.
25. Mai, A.; Artico, M.; Esposito, M.; Ragno, R.; Sbardella, G.; Massa, S. Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. Farmaco, 2003, 58, 231-241.
26. Gallardo-Godoy, A.; Fierro, A.; McLean, T.H.; Castillo, M.; Cassels, B.K.; Reyes-Parada, M.; Nichols, D.E. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J. Med. Chem., 2005, 48, 2407-2419.
27. Hassan, S.Y.; Khattab, S.N.; Bekhit, A.A.; Amer, A. Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 1753-1756.
28. Secci, D.; Bolasco, A.; Chimenti, P.; Carradori, S. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents. Curr. Med. Chem., 2011, 18, 5114-5144.
29. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, biological evaluation and 3DQSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem., 2006, 13, 1411-1428.
30. Kumar, S.; Bawa, S.; Drabu, S.; Gupta, H.; Machwal, L.; Kumar, R. Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives. Eur. J. Med. Chem., 2011, 46, 670-5.
31. Vergel, N.E.; Lopez, J.L.; Orallo, F.; Vina, D.; Buitrago, D. M.; del Olmo, E.; Mico, J.A.; Guerrero, M.F. Antidepressant-like profile and MAO-A inhibitory activity of 4-propyl-2H-benzo[h]-chromen-2-one. Life Sci., 2010, 86, 819-824.
32. Prado-Prado, F.; Garcia-Mera, X.; Escobar, M.; Sobarzo-Sanchez, E.; Yañez, M.; Riera-Fernandez, P.; Gonzalez-Diaz, H. 2D MIDRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. Eur. J. Med. Chem., 2011, 46, 5838-5851.
33. Herraiz, T.; Gonzalez, D.; Ancin-Azpilicueta, C.; Aran, V. J.; Guillen, H. Beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol., 2010, 48, 839-845.
34. Istikoglou, C. I.; Mavreas, V.; Geroulanos, G. History and therapeutic properties of Hypericum Perforatum from antiquity until today. Psychiatrike, 2010, 21, 332-338.
35. Yoshino, S.; Hara, A.; Sakakibara, H.; Kawabata, K.; Tokumura, A.; Ishisaka, A.; Kawai, Y.; Terao, J. Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria. Nutrition, 2011, 27, 847-852.
36. Xu, Y.; Li, S.; Chen, R.; Li, G.; Barish, P.A.; You, W.; Chen, L.; Lin, M.; Ku, B.; Pan, J.; Ogle, W.O. Antidepressant-like effect of low molecular proanthocyanidin in mice: involvement of monoaminergic system. Pharmacol. Biochem. Behav., 2010, 94, 447-453.
37. Li, S.; Wang, C.; Li, W.; Koike, K.; Nikaido, T.; Wang, M.W. Antidepressant-like effects of piperine and its derivative, antiepilepsirine. J. Asian Nat. Prod. Res., 2007, 9, 421-430.
38. Glowinski, J.; Axelrod, J. Inhibition of Uptake of Tritiated-Noradrenaline in the Intact Rat Brain by Imipramine and Structurally Related Compounds. Nature, 1964, 204, 1318-1319.
39. Schildkraut, J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry, 1965, 122, 509-522.
40. Jacobsen, E. The early history of psychotherapeutic drugs. Psycho-pharmacology, 1986, 89, 138-144.
41. Robinson, D.S.; Nies, A.; Ravaris, C.L.; Lamborn, K.R. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial. Arch. Gen. Psychiatry, 1973, 29, 407-413.
42. Rees, L. Treatment of depression by drugs and other means. Nature, 1960, 186, 114-120.
43. Blackwell, B. Hypertensive Crisis Due to Monoamine-Oxidase Inhibitors. Lancet, 1963, 2, 849-850.
44. Lapin, I.P.; Oxenkrug, G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet, 1969, 1, 132-136.
45. Podea, D.; Suciu, R.; Suciu, A.C.; Marinescu, I. The Role of Dopamine in Depression. Rom. J. Psycopharmacol., 2009, 9, 145-153.
46. The NICE guideline on the treatment and management of depression in adults, National Clinical Practice Guideline 90, NICE (National Institute for Health & Clinical Excellence), 2009.
47. Versiani, M.; Mundlm, F.D.; Nardi, A.; Liebowitz, M.R. Tranyl-cypromine in social phobia. J. Clin. Psychopharmacol., 1988, 8, 279-285.
48. Versiani, M.; Nardi, A.E.; Mundim, F.D.; Alves, A.B.; Liebowitz, M.R.; Amrein, R. Pharmacotherapy of social phobia: a Controlled study with moclobemide and phenelzine. Br. J. Psychiatry, 1992, 161, 555-556.
49. Sheehan, D. V. Current concepts in the treatment of panic disorder. J. Clin. Psychiatry, 1999, 60 SUPPL. 18, 16-21.
50. Cyr, M.; Farrar, M.K. Treatment for posttraumatic stress disorder. Ann. Pharmacother., 2000, 34, 366-376.
51. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology, 2004, 25, 215-221.
52. Crupi, R.; Marino, A.; Cuzzocrea, S. New therapeutic strategy for mood disorders. Curr. Med. Chem., 2011, 18, 4284-4298.
53. Abudy, A.; Juven-Wetzler, A.; Zohar, J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs, 2011, 25, 585-596.
54. Krishnan, K.R. Revisiting monoamine oxidase inhibitors. J. Clin. Psychiatry, 2007, 8, 35-41.
55. Gillman P.K. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J. Clin. Psychopharmacol., 2011, 31, 66-74.
56. Uceyler, N.; Hauser, W.; Sommer, C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum., 2008, 59, 1279-1298.
57. Branco, J. C.; Tome, A.M.; Cruz, M.R.; Filipe, A. Pirlindole in the treatment of depression and fibromyalgia syndrome. Clin. Drug Investig., 2011, 31, 675-689.
58. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1527-1533.
59. Lopez-Muñoz, F., Assion, H.J., Alamo, C., García-García, P., Fangmann, P. La introducción clinica de la iproniazida y la imipramina: medio siglo de terapéutica antidepresiva. An. Psiquiatría, 2008, 24, 56-70.
60. Wecker, L.; James, S.; Copeland, N.; Pacheco, M. A. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol. Psychiatry, 2003, 54, 1099-1104.
61. Gordon, M.N.; Muller, C.D.; Sherman, K.A.; Morgan, D.G.; Azzaro, A.J.; Wecker, L. Oral versus transdermal selegiline: antide-pressant-like activity in rats. Pharmacol. Biochem. Behav., 1999, 63, 501-506.
62. Amsterdam, J.D. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry, 2003, 64, 208-214.
63. Nandagopal, J.J.; DelBello, M.P. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert. Opin. Pharmacother., 2009, 10, 1665-1673.
64. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets., 2012, 13, 483-494.
65. Weinstock, M.; Luques, L.; Bejar, C.; Shoham, S. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J. Neural. Transm. Suppl., 2006, 70, 443-446.
66. Sagi, Y.; Weinstock, M.; Youdim, M.B. Attenuation of MPTP- induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem., 2003, 86, 290-297.
67. Youdim, M.B.; Weinstock, M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol., 2001, 21, 555-573.
68. Youdim, M.B.; Amit, T.; Bar-Am, O.; Weinreb, O.; Yogev-Falach, M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox. Res., 2006, 10, 181-192.
69. Pal, A.; Nayak, S.; Sahu, P.K.; Swain, T. Piperine protects epilepsy associated depression: a study on role of monoamines. Eur. Rev. Med. Pharmacol. Sci., 2011, 15, 1288-1295.
70. Johnson, S.; Tazik, S.; Lu, D.; Johnson, C.; Youdim, M.B.; Wang, J.; Rajkowska, G.; Ou, X.M. The new inhibitor of Monoamine Oxidase, M30, has a neuroprotective effect against dexamethasone- induced brain cell apoptosis. Front. Neurosci., 2010, 4, 180.
71. Gal, S.; Fridkin, M.; Amit, T.; Zheng, H.; Youdim, M. B. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural. Transm. Suppl., 2006, 70, 447-456.
72. Girard, P.; Verniers, D.; Pansart, Y.; Gillardin, J.M. Efficacy of moclobemide in a rat model of neurotoxicant-induced edema. Can. J. Physiol. Pharmacol., 2007, 85, 556-561.
73. Naoi, M.; Maruyama, W.; Inaba-Hasegawa, K.; Akao, Y. Type A monoamine oxidase regulates life and death of neurons in neurode-generation and neuroprotection. Int. Rev. Neurobiol., 2011, 100, 85-106.
74. Naoi, M.; Maruyama, W. Monoamine oxidase inhibitors as neuro-protective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des., 2010, 16, 2799-2817.
75. Edmondson, D.E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys., 2007, 464, 269-276.
76. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. USA., 2005, 102, 12684-12689.
77. Schoerlin, M.P.; Blouin, R.A.; Pfefen, J.P.; Guentert, T.W. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine. Acta Psychiatr. Scand. Suppl., 1990, 360, 98-100.
78. Jedrychowski, M.; Feifel, N.; Bieck, P.R.; Schmidt, E.K. Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine. J. Pharm. Biomed. Anal., 1993, 11, 251-255.
79. Rang, H.P., Dale, M.M., Ritter, J.M., Flower, R.J. Farmacologia; 6 ed.; Elsevier: Barcelona, España, 2006.
80. Dollery, C.T. Therapeutic drugs. Churchill Livingstone: London, 1999.
81. Baker, G.B.; Urichuk, L.J.; McKenna, K.F.; Kennedy, S.H. Metabolism of monoamine oxidase inhibitors. Cell. Mol. Neurobiol., 1999, 19, 411-426.
82. Mayersohn, M.; Guentert, T.W. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin. Pharmacokinet., 1995, 29, 292-332.
83. Shulman, K.I.; Walker, S.E.; MacKenzie, S.; Knowles, S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J. Clin. Psychopharmacol., 1989, 9, 397-402.
84. Wimbiscus, M.; Kostenko, O.; Malone, D. MAO inhibitors: risks, benefits, and lore. Cleve. Clin. J. Med., 2010, 77, 859-882.
85. Delini-Stula, A.; Radeke, E.; Waldmeier, P.C. Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol. Ser., 1988, 5, 147-158.
86. Lotufo-Neto, F.; Trivedi, M.; Thase, M.E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsycho-pharmacology, 1999, 20, 226-247.
87. Fiedorowicz, J.G.; Swartz, K.L. The role of monoamine oxidase inhibitors in current psychiatric practice. J. Psychiat. Pract., 2004, 10, 239-248.
88. Volz, H.P.; Gleiter, C.H. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging, 1998, 13, 341-355.
89. Nelson, S.D.; Mitchell, J.R.; Timbrell, J.A.; Snodgrass, W.R.; Corcoran, G.B. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science, 1976, 193, 901-903.
90. Pons, C.; Dansette, P.M.; Gregeois, J.; Homberg, J.C.; Billett, E.E.; Mansuy, D. Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. Biochem. Biophys. Res. Commun., 1996, 218, 118-124.
91. Pall, M.; Bested, K.M.; Eriksen, N.D. Poisoning with a reversible and selective monoaminooxidase inhibitor. Ugeskr. Laeger, 1997, 159, 4859-4860.
92. Halle, M.H.; Del Medico, V.J.; Dilsaver, S.C. Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatr. Scand., 1991, 83, 238-239.
93. Baumbacher, G.; Hansen, M.S. Abuse of monoamine oxidase inhibitors. Am. J. Drug Alcohol Abuse, 1992, 18, 399-406.
94. Curtin, F.; Berney, P.; Kaufmann, C. Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. J. Psychopharmacol., 2002, 16, 271-272.
95. Browne, B.; Linter, S. Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. Br. J. Psychiatry, 1987, 151, 210-212.
96. Bem, J.L.; Peck, R. Dextromethorphan. An overview of safety issues. Drug Saf., 1992, 7, 190-199.
97. Calvisi, V.; Ansseau, M. Clinical case of the month. Mental confusion due to the administration of tramadol in a patient treated with MOAI. Rev. Med. Liege, 1999, 54, 912-913.
98. Ener, R.A.; Meglathery, S.B.; Van Decker, W. A.; Gallagher, R. M. Serotonin syndrome and other serotonergic disorders. Pain Med., 2003, 4, 63-74.
99. Marangell L. B. Switching antidepressants for treatment-resistant major depression. J. Clin. Psychiatry, 2001, 62 SUPPL. 18, 12-17.